resTORbio, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Boston MA United States (2016)
Status: Acquired by Adicet Bio (2020)

Organization Overview

First Clinical Trial
2017
NCT03373903
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Restorbio Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

dactolisib (3 trials)

rtb101 (2 trials)

Drugs in Phase 2 Trials (1)

everolimus (zortress) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Infections (Phase 2)

Respiratory Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3